Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 69

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 69
---
 program.

U.S.-China trade relations may adversely impact our supply chain operations and business.

The U.S. and Chinese governments have taken certain actions that change trade policies, including tariffs that affect certain products which are manufactured
in China and mutual exchange of certain types of data. Due to our reliance on WuXi Biologics and Hangzhou DAC to supply and manufacture our product candidates and their components, we are reliant on collaborating with a company with
significant operations in China. It is unknown whether and to what extent new tariffs, laws or regulations will be adopted that increase the cost or feasibility of importing and/or exporting products, components and information
from China to the United States and vice versa. Further, the effect of any such new tariffs or actions on our industry and customers is unknown and difficult to predict. As additional new tariffs, legislation and/or regulations are
implemented, or if existing trade agreements are renegotiated or if China or other affected countries take retaliatory trade actions, such changes could have a material adverse effect on our clinical development plans, business, financial
condition, results of operations or cash flows.

Risks Related to Aadi

For more information regarding risks related to Aadi’s historical business, as well as other risk factors applicable to Aadi and its industry, see
“Aadi Risk Factors” beginning on page 229.

- 46 -

THE DIVESTITURE

The following is a discussion of the Divestiture. The description of the Divestiture Agreement in this section and elsewhere in this proxy statement is qualified in its entirety by reference to the complete text of the Divestiture Agreement, which is attached as Annex A to this proxy statement. This summary does not purport to be complete and may not contain all of the information about the Divestiture that is important to you. You are encouraged to read the Purchase Agreement carefully and in its entirety, as it is the legal document that governs the Divestiture.

Parties to the Divestiture

Aadi Bioscience, Inc. (Aadi)

Aadi is a precision
oncology company making bold choices in applying technology to efficiently deliver improved therapies for people with difficult-to-treat cancers. Aadi is a corporation organized under the laws of the State of Delaware. Shares of Aadi common stock
are listed on the Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “AADI.”

Aadi Subsidiary, Inc. (Aadi Sub)

Aadi Sub is wholly owned subsidiary of Aadi and the